Literature DB >> 27177234

Piperazine derivatives for therapeutic use: a patent review (2010-present).

Anuj K Rathi1, Riyaz Syed2, Han-Seung Shin3, Rahul V Patel3.   

Abstract

INTRODUCTION: Piperazine, a six membered nitrogen containing heterocycle, is of great significance to the rational design of drugs. This moiety can be found in a plethora of well-known drugs with various therapeutic uses, such as antipsychotic, antihistamine, antianginal, antidepressant, anticancer, antiviral, cardio protectors, anti-inflammatory, and imaging agents. Slight modification to the substitution pattern on the piperazine nucleus facilitates a recognizable difference in the medicinal potential of the resultant molecules. AREAS COVERED: Scifinder was the main source used to search for patents containing piperazine compounds with therapeutic uses. The article describes a variety of molecular designs bearing piperazine entity furnishing CNS agents, anticancer, cardio-protective agents, antiviral, anti-tuberculosis, anti-inflammatory, antidiabetic, and antihistamine profiles, as well as agents relieving pain and useful in imaging applications. EXPERT OPINION: The great interest gathered to explore piperazine based molecules in relatively few years reflects the broad potential of the entity. Earlier, this scaffold was considered to express CNS activity only. However, a significant increase in research covering studies of several different activities of piperazine ring suggest a successful emergence of the pharmacophore. Certain patents outlined in the present article recommend that piperazines can be a flexible building block to discover drug-like elements and modification of substituents present on the piperazine ring may have a significant impact on the pharmacokinetic and pharmacodynamics factors of the resulting molecules. This article aims to provide insights to piperazine based molecular fragments that would assist drug discoverers to rationally design molecules for various diseases. We anticipate, and highly recommend, further therapeutic investigations on this motif.

Entities:  

Keywords:  Anticancer; CNS disorder; anti-inflammatory; anti-tuberculosis; antihistamine; antiviral; cardio-protective; imaging agents; pain; piperazine

Mesh:

Substances:

Year:  2016        PMID: 27177234     DOI: 10.1080/13543776.2016.1189902

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  21 in total

Review 1.  Antipsychotic inductors of brain hypothermia and torpor-like states: perspectives of application.

Authors:  Yury S Tarahovsky; Irina S Fadeeva; Natalia P Komelina; Maxim O Khrenov; Nadezhda M Zakharova
Journal:  Psychopharmacology (Berl)       Date:  2016-12-08       Impact factor: 4.530

2.  Synthesis and Biological Evaluation of Novel Benzhydrylpiperazine-Coupled Nitrobenzenesulfonamide Hybrids.

Authors:  Vallabhaneni S Murthy; Yasinalli Tamboli; Vagolu Siva Krishna; Dharmarajan Sriram; Fang Xiong Zhang; Gerald W Zamponi; Vijayaparthasarathi Vijayakumar
Journal:  ACS Omega       Date:  2021-03-31

3.  Development of novel N-(6-methanesulfonyl-benzothiazol-2-yl)-3-(4-substituted-piperazin-1-yl)-propionamides with cholinesterase inhibition, anti-β-amyloid aggregation, neuroprotection and cognition enhancing properties for the therapy of Alzheimer's disease.

Authors:  Chandra Bhushan Mishra; Shruti Shalini; Siddharth Gusain; Amresh Prakash; Jyoti Kumari; Shikha Kumari; Anita Kumari Yadav; Andrew M Lynn; Manisha Tiwari
Journal:  RSC Adv       Date:  2020-05-05       Impact factor: 3.361

4.  Brønsted acid-mediated cyclization-dehydrosulfonylation/reduction sequences: An easy access to pyrazinoisoquinolines and pyridopyrazines.

Authors:  Ramana Sreenivasa Rao; Chinnasamy Ramaraj Ramanathan
Journal:  Beilstein J Org Chem       Date:  2017-03-07       Impact factor: 2.883

5.  Piperazinyl fragment improves anticancer activity of Triapine.

Authors:  Marta Rejmund; Anna Mrozek-Wilczkiewicz; Katarzyna Malarz; Monika Pyrkosz-Bulska; Kamila Gajcy; Mieczyslaw Sajewicz; Robert Musiol; Jaroslaw Polanski
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

6.  Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa.

Authors:  Nadezhda Novichikhina; Ivan Ilin; Anna Tashchilova; Alexey Sulimov; Danil Kutov; Irina Ledenyova; Mikhail Krysin; Khidmet Shikhaliev; Anna Gantseva; Ekaterina Gantseva; Nadezhda Podoplelova; Vladimir Sulimov
Journal:  Molecules       Date:  2020-04-19       Impact factor: 4.411

7.  Rhein Derivative 4F Inhibits the Malignant Phenotype of Breast Cancer by Downregulating Rac1 Protein.

Authors:  Xinxiao Li; Yunfeng Liu; Yuhua Zhao; Wei Tian; Lina Zhai; Huifeng Pang; Jiankang Kang; Huaxin Hou; Yanhua Chen; Danrong Li
Journal:  Front Pharmacol       Date:  2020-05-28       Impact factor: 5.810

8.  Design, Synthesis, and Antiproliferative Evaluation of Novel Coumarin/2-Cyanoacryloyl Hybrids as Apoptosis Inducing Agents by Activation of Caspase-Dependent Pathway.

Authors:  Yu-Ying Zhang; Qian-Qian Zhang; Jia-Li Song; Liang Zhang; Cheng-Shi Jiang; Hua Zhang
Journal:  Molecules       Date:  2018-08-07       Impact factor: 4.411

9.  Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents.

Authors:  Burcu Çalışkan; Esra Sinoplu; Kübra İbiş; Ece Akhan Güzelcan; Rengül Çetin Atalay; Erden Banoglu
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

10.  Study of Iron Piperazine-Based Chelators as Potential Siderophore Mimetics.

Authors:  Pauline Loupias; Isabelle Dechamps-Olivier; Laurent Dupont; Pierre Vanlemmens; Catherine Mullié; Nicolas Taudon; Anne Bouchut; Alexandra Dassonville-Klimpt; Pascal Sonnet
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.